ABOUT SUMMIT:
Ivonescimab, known as SMT112, is a novel, potential first-in-class investigational
bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity when in the presence of both PD-1 and VEGF.
Summit has begun its clinical development of ivonescimab in non-small cell lung cancer (NSCLC), with three active Phase III trials:
- HARMONi is a Phase III clinical trial which intends to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a 3rd generation EGFR TKI (e.g., osimertinib).
- HARMONi-3 is a Phase III clinical trial which is designed to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.
- HARMONi-7 is a Phase III clinical trial which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression.
Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. Ivonescimab was approved for marketing authorization in China in May 2024. Ivonescimab was granted Fast Track designation by the US Food & Drug Administration (FDA) for the HARMONi clinical trial setting.
EXPERIENCE, EDUCATION AND SPECIALIZED KNOWLEDGE AND SKILLS:
- Bachelor’s degree in finance, business, accounting or related field preferred
- CPA or progress toward designation preferred
- A minimum of 4+ years of experience in accounting
- Experience in the life sciences industry, with prior exposure to clinical study accruals strongly preferred
- Strong understanding of GAAP, internal controls, SOX controls and month-end close procedures required
- Must be proficient in handling large-scale financial data using Excel and financial systems for accurate analysis and reporting
- High level of accuracy and attention to detail
- Demonstratable experience of working within a fast-paced finance function
- Demonstratable experience of prioritizing workload and managing multiple tight deadlines effectively under pressure in a fast-paced environment
- Excellent communication skills with the ability to forge strong internal and external working relationships, and the confidence to challenge information constructively
- Enthusiastic team player with an approachable manner and an ability to engage with colleagues across the business with a constructive and can-do attitude to deliver the successful completion of team outputs within required deadlines.
The pay range for this role is $134,000-$155,000 annually. Actual compensation packages are based on several factors that are unique to each candidate, including but not limited to skill set, depth of experience, certifications, and specific work location. This may be different in other locations due to differences in the cost of labor. The total compensation package for this position may also include bonus, stock, benefits and/or other applicable variable compensation.
Summit does not accept referrals from employment businesses and/or employment agencies in respect of the vacancies posted on this site. All employment businesses/agencies are required to contact Summit’s Talent Acquisition team at recruiting@smmttx.com to obtain prior written authorization before referring any candidates to Summit
Incase you would like to apply to this job directly from the source, please click here